Cytokine signaling pathways are frequent targets of oncogenic mutations in acute myeloid leukemia (AML), promoting proliferation and survival. We have previously shown that the transcription factor PLAGL2 promotes proliferation and cooperates with the leukemia fusion protein Cbfb-SMMHC in AML development. Here, we show that PLAGL2 upregulates expression of the thrombopoietin receptor Mpl, using two consensus sites in its proximal promoter. We also show that Mpl overexpression efficiently cooperates with Cbfb-SMMHC in development of leukemia in mice. Finally, we demonstrate that PlagL2-expressing leukemic cells show hyper-activation of Jak2 and downstream STAT5, Akt and Erk1/2 pathways in response to Thpo ligand. These results show that PlagL2 expression activates expression of Mpl in hematopoietic progenitors, and that upregulation of wild-type Mpl provides an oncogenic signal in cooperation with CBFb-SMMHC in mice.
Introduction
Acute myeloid leukemia (AML) results from the accumulation of genetic alterations in hematopoietic progenitors (HPs) that alter survival and differentiation programs. The study of these alterations is key for understanding the mechanism of leukemia development. The chromosome 16 inversion inv(16)(p13;q22), called inv16, is a frequent mutation found in AML cases, which creates the leukemia fusion gene CBFB-MYH11. 1 The Cbfb-SMMHC protein encoded by the fusion gene induces accumulation of preleukemic myeloid progenitors unable to differentiate, which transform into full-blown leukemia in synergy with mutations that promote proliferation and survival. 2, 3 A fraction of inv16-AML samples present activating mutations in genes encoding components of the receptor tyrosine kinase signaling pathways, including KIT and FLT3, and the their downstream GTPases NRAS and KRAS. [4] [5] [6] [7] [8] These mutations produce ligand-independent constitutively active signaling that enhances the expansion and survival of leukemic blasts. We have previously shown that the zinc finger PLAG transcription factors, Plag1 and PlagL2, have similar capacity to induce proliferation of HPs and cooperate with Cbfb-SMMHC in AML development. 9, 10 The PLAG factors bind to the GRGGC(N) 6À8 RGGK consensus site in regulatory regions of target genes to activate transcription, such as the promoter 3 of the insulin-like growth factor 2 gene. 11 The PLAG oncogenic activity has also been reported in chronic lymphocytic leukemia, breast cancer and salivary gland tumors. [12] [13] [14] However, little is known on how PLAG induces transformation in HPs and leukemia blasts.
In this study, we use gene-expression profile analysis of HPs and leukemic cells expressing PLAGL2 to identify genes that are consistently deregulated by PLAGL2. We identify the thrombopoietin receptor Mpl as a downstream target, using gene profile analysis, and validated its expression levels using quantitative reverse transcription-PCR and flow cytometry. Furthermore, we identify two PLAG-binding sites conserved in mammals in Mpl proximal promoter using luciferase reporter and electrophoretic mobility shift assays. We determined that Mpl is a key downstream mediator of PLAGL2 leukemogenesis as overexpression of wild-type Mpl efficiently cooperates with CBFb-SMMHC in leukemia development using transplantation assays. The leukemic cells expressing PLAGL2 exhibit sensitivity to Thpo ligand as evidenced by increased phosphorylation of Jak2, Erk1/2, Akt and Stat5. Together, these results demonstrate that PLAGL2 regulates Mpl expression, and that upregulation of wild-type Mpl cooperates with CBFB-MYH11 in leukemia development in mice.
Materials and methods

Microarray analyses
Sample preparation. For infected bone marrow (BM)-HP cells, 129SvEv Cbfb þ /56M ;Mx1Cre mice were treated with 150 mg/kg 5-fluorouracil, and BM cells were harvested 5 days later. Cells were subjected to red-blood-cell lysis solution (Purgene, Gentra Systems, Minneapolis, MN, USA), and spininfected with two rounds of retrovirus (MIG or MIG-PLAGL2) as previously described. 10 The green-fluorescent protein (GFP)positive cells were sorted by fluorescence-activated cell sorting and total RNA was immediately isolated (samples wild-type (wt)-MIG1, wt-MIG2, wt-P1 and wt-P2). The mouse AML cells were generated using Cbfb-MYH11 conditional knock-in mice as previously described. 3 AML cells were isolated from spleen of three independent leukemic mice expressing MIG-PLAGL2 (samples AML-P1, AML-P2 and AML-P3) and from three independent leukemic mice with low Plagl2 levels (AML-x1, AML-x2, AML-x3). In all cases, RNA was extracted with Trizol (Invitrogen, Carlbad, CA, USA) and cleaned with RNA-Easy columns (Qiagen, Valencia, CA, USA). Complementary DNA was synthesized using the Superscript II (Invitrogen), and Biotin-labeled cRNA was subsequently synthesized using RNA-transcript labeling kit (Affymetrix, Santa Clara, CA, USA). Labeled cRNA (10 mg) was fragmented and hybridized to Affymetrix Mouse Genome 430 2.0 Chip Arrays (Affymetrix).
Data analysis
To identify transcripts that were differentially expressed in MIG-PLAGL2, AML-PLAGL2 and AML samples, we used the GeneSpring (version 7.3; http://www.silicongenetics.com) and GENECLUSTER (version 2.0; http://www-genome.wi.mit.edu) software packages. The expression values of each probe set in each of the MIG-PLAGL2, AML-PLAGL2 and AML samples were normalized to that of the MIG control number one or number two samples. For a given transcript to be considered as differentially expressed in MIG-PLAGL2, AML-PLAGL2 and AML samples, it had to meet the following three criteria. First, the signal values in these samples and the MIG control sample had to exhibit a relative difference of at least a factor of 2 and an absolute difference of 100 U. Second, changes of comparable magnitude had to be reproduced in two out two independent experiments for the MIG-PLAG2 sample or three out three independent experiments for the AML-PLAGL2 and AML samples when compared with MIG controls. Third, when statistical group comparisons (Welch's approximate t-test) were applied to the raw signal values of the MIG control samples and the MIG-PLAGL2, AML-PLAGL2 or AML samples, it yielded a significance value of Pp0.05. Transcripts differentially expressed in MIG-PLAGL2, AML-PLAGL2 or AML samples were subjected to hierarchical clustering analysis using the GeneSpring (version 7.3) software package. For this analysis, the signal value of each transcript in each of the samples was normalized to the corresponding value of the MIG control number one sample. The resulting ratios were subjected to twodimensional clustering by using the average linkage algorithm and the standard correlation coefficient as a distance metric.
Reverse transcriptase-and quantitative Reverse transcription-PCR analyses
RNA from mouse BM and AML cells was extracted with Trizol (Invitrogen). First-stand complementary DNA was generated by using 2 mg RNA, 1 U Superscript-II reverse transcriptase (Invitrogen), and 0.5 mM oligo-dT primer in a 20-ml reaction. SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) was used for quantitative PCR according to the manufacturer's instructions. Mpl primers were Mplx1 and Mplx2 and b-actin primers were ActbF1 and ActbR1 (Supplementary Table 1 ). Quantitative PCR was performed in an ABI PRISM 7000 Sequence Detection System (Applied Biosystems). Samples were normalized to b-actin transcript levels, and relative values were determined using standard curve method.
Retroviral production
The MIG-Mpl construct was generously provided by Harvey Lodish (Massachusetts Institutes of Technologies, Cambridge, MA, USA). The MIG-MplY mutant construct was generated by PCR using primers pMSCV1 and MplY112rev, cut with EcoR1 and Xho1, and cloned into MIG. Phoenix packaging cells (Gary Nolan, Stanford University, Stanford, CA, USA) were co-transfected with 2 mg retroviral constructs, 2 mg Psi-Eco packaging plasmid with Effectene (Qiagen) according to manufacturer's protocol. Retrovirus supernatants were taken at 48, 56 and 72 h and titered in by GFP-fluorescence-activated cell sorting analysis.
Bone marrow transduction and transplantation
Endogenous Cbfb-MYH11 expression was induced in Cbfb 56M/ þ Mx1Cre conditional knock-in mice 3 using the Mx1Cre transgenic system. 15 Briefly, mice were injected with three doses every other day of polyinosinic-polycytidylic acid (Sigma, St Louis, MO, USA) at 3-to 5-weeks of age, treated with 150 mg/kg 5-fluorouracil, and BM cells were harvested 5 days later. Efficiency of Cre-mediated Cbfb-MYH11 induction was consistently above 90%. 3 The BM progenitor cells were spininfected twice with retrovirus supernatant, and 5 Â 10 5 -1 Â 10 6 BM cells transplanted by intravenous injection (i.v.) into 4-to 6-week-old sublethally irradiated (650 rads) 129SvEv wild-type recipient mice. Mice were under daily observation for early signs of leukemia. These signs included limited motility, pale paws and dehydration. At first signs of illness, peripheral blood was analyzed for the presence of immature cells. Fluorescenceactivated cell sorting analysis of peripheral blood was performed by using antibodies to cell-surface markers Gr-1, CD11b, B220, CD3, Ter119 and c-kit (BD Biosciences, San Diego, CA, USA). For flow cytometry analysis of Mpl receptor expression, a polyclonal rabbit anti-Mpl extracellular domain antibody (provided by Harvey Lodish, Whitehead Institute for Biomedical Research, Cambridge, MA, USA) and a PE-anti-rabbit secondary antibody were used. For secondary transplantations, leukemic cells were harvested from the BM or spleen of affected mice in RPMI 1640 and 20% fetal bovine serum (both from Invitrogen), and 1 Â 10 6 single-cell suspension aliquots were transplanted i.v. into sub-lethally irradiated 4-to 6-week-old 129SvEv recipients.
Immunoblot analyses
Cryopreserved AML cells were thawed and immediately serum starved in RPMI media with 1% bovine serum albumin for 60 min at 37 1C (Invitrogen,). Cells were then incubated with RPMI media with 0.1% bovine serum albumin and 0, 5, 25 or 50 ng/ml Thpo (Peprotech, Rockyhill, NJ, USA) for 10 min. Cells were washed with PBS and resuspended in RIPA buffer with protease-inhibitor-cocktail III (Calbiochem, Darmstadt Germany). Antibodies included anti-Jak2 (cat#sc-294; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), and antiphospho-Jak2-Tyr221 (cat#3774), anti-phospho-Stat5-Tyr694 (cat#9351), anti-Stat5 (cat#9310), anti-phospho-Akt-Ser273 (cat#4058), anti-Akt (cat#9272), anti-phospho-Erk1/2 -Thr202/ Tyr204 (cat#9101) and anti-Erk1,2 (cat#9102; all from Cell Signaling Technology, Danvers, MA, USA).
DNA sequence analysis
The search for PLAG consensus site GRGGC (6) (7) (8) RGGK was analyzed using the UCSC Genome Browser on Mouse July 2007 (NCBI37/mm9) Assembly (http://genome.ucsc.edu). Promoter regions were defined as 1000 bp upstream and 200 bp downstream of transcription start site, with this site as position 1000 ( Supplementary Table 1 ). Evolutionary conservation of PLAG sites among six mammal species (human, orangutan, mouse, rat, dog and horse) was estimated. The sequence conservation analysis at the Mpl proximal promoter was performed using ClustalW-Alignment Analysis from MacVector9.5.2 (MacVector Inc., Cary, NC, USA).
Luciferase assays
A 300 bp fragment of the Mpl proximal promoter was amplified with primers MPLFLPromkpnF and MPLFLpromBglR using PFU (Stratagene, La Jolla, CA, USA), and the amplicon was digested with KpnI and BglII and cloned into pGL3-Basic (Promega, Madison, WI, USA). Mutants were constructed by overlapping PCR with primers Mpls1F and Mpls1R for 'site-1', Mplps2F and Mplps2R for 'site-2', and Mplps3F and Mplps3R for 'site-3' (Supplementary Table 1 ). The mutant primers were used with primers MPLFLpromkpnF and MPLFLpromBglR to amplify overlapping fragments that were annealed, digested with KpnI and BglII and cloned into the PGL3-basic vector. Constructs were transfected into NIH3T3 cells along with MhCD4 or MhCD4-PLAGL2 and PRL-TK with Effectene (Qiagen). Cells were analyzed for luciferase levels with the Dual-Luciferase Reporter Assay System (Promega).
Electrophoretic mobility shift assay
The electrophoretic mobility shift assay was performed as previously described. 16 Briefly, 3T3 cells transfected with MIG-PlagL2 were used for isolation of nuclear proteins and added to protein-DNA binding reactions with double-stranded DNA oligos representing PlagL2-binding sites in the Mpl promoter. The sequence for DNA oligos P1ss and P1as, P2ss and P2as, P3ss and P3as, mutP1ss and mutP1as, mutP2ss and mutP2as, and mutP3ss and mutP3as are shown in Supplementary Table 1 .
The P1ss, P2ss and P3ss oligos were radioactively labeled with 32 P using OptiKinase (USB, Cleveland, OH, USA), and the excess 32 P-gATP was removed by purifying the labeled oligos using G-25 Mini Quick Spin Oligo columns (Roche, Basel, Switzerland). The oligos were annealed with equal amounts of antisense oligos (P1as, P2as, P3as respectively) to obtain a double stranded labeled oligo with a PlagL2-binding site. In all, 100 pg of the oligo was used for each binding reaction. Cold competitors and mutant competitors were obtained the same way, but without labeling the oligos. When using cold competitors (wild type or mutant), a 1:200 molar ratio of labeled and cold oligo was used. Constant DNA amount was maintained by adding scrambled oligos Sss and Sas. The protein-DNA binding reactions were loaded onto a 4% polyacrylamide gel, ran until unlabeled 32 P-gATP went out into buffer, dried and exposed for 24 h.
Cytology analysis
Cells from peripheral blood smears were stained with Wright-Giemsa. Pictures were taken using a Zeiss Axioskop 40 microscope using Â 100 lenses and a Zeiss AxioCam MRc camera and software.
Results
Mpl is upregulated by the transcription factor PLAGL2 in HPs and AML blasts
We have previously shown that the transcription factor PLAGL2 induces AML in synergy with Cbfb-SMMHC in mice. 10 To identify PLAGL2 target genes that participate in leukemia development, we defined a group of genes consistently deregulated by PLAGL2 by assessing those genes consistently deregulated in BM-HP and AML blasts expressing PLAGL2. The HPs from Cbfb þ /MYH11 conditional knock-in mice expressing Cbfb-MYH11 were transduced with a pMSCV-IRES-GFP (MIG) or pMSCV-PLAGL2-IRES-GFP (PL2-MIG) retrovirus ( Supplementary   Figure 1a ). The RNA from GFP sorted cells was used in a gene profile analysis using two independent samples per group, and represent the 'early deregulated gene-set'. In addition, the expression profiles of six mouse AML samples expressing Cbfb-MYH11, three expressing (P þ 1AML to-P þ 3AML) and three not expressing PLAGL2 (P-1AML to-P-3AML), were analyzed (experimental design in Supplementary Figure 1b) . Two-dimensional hierarchical clustering of the 10 samples was performed using GeneSpring software ( Supplementary Figure 1c) . Thirty-three probes identified 23 genes consistently upregulated over twofold in PLAGL2 expressing samples (Figure 1a ). These included upregulation of transcripts for the thrombopoietin receptor Mpl, the G-protein couple receptors Gpr56, Prokr1 and Gpr124, the endothelial protein-C receptor, the vitamin-D receptor, endoglin and collagenase genes Col18a1 and Col4a2. In addition, the transcripts for the extracellular matrix proteins tenascin-XB and Spondin-2, the ubiquitin ligase Cullin-7, the actin-associated Cyb5r3 and Janus kinase Jak3 were consistently increased by PLAGL2. Consistent with the reported transcription activation role of PLAGL2, this analysis did not identify downregulated genes. 17, 18 Expression of the Mpl probes was confirmed using scatter-plot of bone marrow cells transduced with PLAGL2 or MIG in the microarrays ( Supplementary Figure 2A) and among all the samples (Supplementary Figure 2B) . The presence of PLAG consensus GRGGC RGGK sites 11 was searched in a 1200 bp window (1000 bp upstream and 200 bp downstream of the gene transcription start), with the start site as position 1000 (Supplementary Table 2 ). The conservation of these sites in five mammal species was analyzed using the UCSC Genome Sequence. From the 23 identified genes, three genes (Mpl, Ccdc8 and Eng) showed high conservation in all sites, whereas four genes (Hif3a and three genes with unknown function) have at least one conserved site.
Considering that PLAGL2 induces proliferation and replating capacity of HPs, 10 and the high conservation of the three PLAG sites in its promoter region, we focused our study on the cytokine thrombopoietin receptor Mpl. Quantitative reverse transcription-PCR analysis revealed that the level of Mpl transcript was increased over 100-fold 48 h after transduction (Figure 1b, lanes 1 and 2) . A similar increase (30-to 500-fold) was observed in AML cells expressing PLAGL2 when compared with AML cells not expressing PLAGL2 (Figure 1b, lanes 3-10) . In addition, the levels of Mpl receptor in membrane were markedly increased in AML cells expressing PLAGL2 using flow cytometry (Figure 1c ).
PLAGL2 induces expression of the Mpl proximal promoter
The Mpl gene consists of 12 exons highly conserved in mammals and its expression is regulated from a proximal promoter spanning B200 bp upstream of the translation start site (Figure 2a, top) . This region is highly conserved in the mammalian genomes (30 way multiz-alignment and conservation; USCS-Mouse genome Browser; Figure 2a , middle). The Mpl proximal promoter (À189 to þ 3 from translation start site) is highly conserved in mammals, including human, monkey, mouse, dog, horse and cow genomes (ClustalW sequence alignment; Figure 2a , bottom). This region has three PLAGconsensus-binding sites. To test whether PLAGL2 could directly activate Mpl expression, we tested PLAGL2 responsiveness of a luciferase reporter carrying the Mpl proximal promoter in NIH3T3 cells. PLAGL2 activated the reporter over 30-fold relative to control (Figure 2b, lanes 1 and 2) . The introduction of previously described 11 point mutations in PLAG-binding PlagL2 directly activates Mpl receptor SF Landrette et al sites 1 (m1) and 2 (m2) resulted in a two-and fivefold reduction in luciferase activity, respectively (Figure 2b , columns 3-6), indicating that these sites are critical for PLAGL2-induced Mpl transcription. Conversely, mutation of the third PLAG site (m3) did not change significantly the PLAGL2 responsiveness, suggesting that this site may not participate in the Mpl promoter activity (Figure 2b, columns 7 and 8) . Importantly, mutation of all three PLAG-binding sites totally obliterated PLAGL2 responsiveness of the reporter, confirming that binding of PLAGL2 to the promoter is necessary for transcriptional activation (Figure 2b , columns 9 and 10). To validate PLAGL2 binding to these sites, we performed electrophoretic mobility shift assays using oligonucleotides covering each of the three Mpl-binding sites (o) and a combination of labeled oligonucleotides with cold competitor (c) or mutated competitor (m) oligonucleotides (Figure 2c ). These assays show that P1 and P2 sites bind to PLAGL2 with specificity, but P3 site binding is poorly competed with cold competitor. These results suggest that PLAGL2 can directly activate the Mpl proximal promoter using the P1 and P2-binding sites.
Overexpression of Mpl induces AML in cooperation with CBF fusion genes
As PLAGL2 induces expression of Mpl in HPs and AML cells, we asked whether Mpl expression is a key event triggered by PLAGL2 in leukemia development. We tested whether co-expression of Cbfb-MYH11 and Mpl is sufficient for AML development in a BM transplantation assay (Figures 3a and b , and 'Materials and Methods'). All of the mice transplanted with BM cells expressing Cbfb-MYH11/MIG-Mpl (n ¼ 14) readily developed leukemia between 4 and 10 weeks post-transplantation (Figure 3c , blue line). Control groups remained healthy over 5 months, including Cbfb-MYH11/MIG (n ¼ 10) or MIG-Mpl (n ¼ 8) transplanted mice (Figure 3c , black line). Secondary transplantation of AML cells into sub-lethally irradiated recipients succumbed with leukemia with a median latency of 4 weeks (Figure 3c , green line; n ¼ 11) confirming the leukemic nature of the disease. The pathology of disease in Cbfb-MYH11/ Mpl AML mimics that of Cbfb-MYH11/MIG-PLAGL2 leukemia previously described. 9, 10, 19 Briefly, we found a significant increase of GFP( þ ), Kit( þ ) immature cells in peripheral blood (Figure 3d ), confirming the presence of the MIG-Mpl retrovirus, and were lineage negative (Lin: CD3, Gr-1, B220, Ter119 and Mac-1). These cells were blast-like cells with dark and pigmented cytoplasm, and monocytic-like cells with lobulated nucleus (Figure 3e , red arrow and asterisks respectively). Moribund mice also displayed infiltration of leukemic cells into the spleen, causing a significant enlargement (Figure 3f ). The Mpl mutation tyrosine to phenylalanine at amino acid 112 (Y112F) in the carboxyl-terminus largely reduces downstream signaling through the PI3k/Akt, Ras/Erk and Stat3/5 kinase activity. Ligand stimulation of Mpl results in the phosphorylation of JAK2 kinase, a required step for phosphorylation of cytoplasmic residues of Mpl, which then triggers activation of AKT/mTOR, STAT3/5 and RAS/ERK cascades. 23 We analyzed the phosphorylation status of Jak2 in CBFb-MYH11-AML cells expressing PLAGL2 (PL2 þ ) or not (PL2-) cultured in presence of Thpo after serum starvation. We found increased phospho-Jak2 levels in presence of Thpo only in samples expressing PLAGL2 (Figure 4a ). In addition, the phosphorylation of downstream signals Akt1, Stat5 and Erk1/2 was increased accordingly in response to Thpo in these AML samples (Figure 4b ). Of note, phopspho-Akt levels were significantly increased on Thpo induction (Figure 4c ). These results demonstrate that Cbfb-MYH11-AML cells expressing PLAGL2 have an activated Mpl signaling pathway in response to Thpo ligand.
Discussion
The leukemias with core-binding factor inv(16)(p13;q22) frequently present oncogenic mutations in receptor tyrosine-kinase pathway proteins KIT, FLT3 and RAS, which provide proliferation and survival capacity to hematopoietic blasts. 8 We have previously shown that the related transcription factors PLAG1 and PLAGL2 cooperate with CBFb-SMMHC in leukemia development. 10 This study shows that the transcription factor PLAGL2 activates Mpl receptor, inducing activation of the Erk, Stat, Akt pathways. The members of the PLAG zinc finger transcription factors PLAG1 and PLAGL2 have been shown to activate growth factor associated genes, including IGFII and CLF1, in epithelial cells. 24 We found that the PLAG factors promote proliferation of HPs and participate in AML development. 9, 10 Here, we designed a gene-expression profiling approach to identify genes consistently deregulated by PLAGL2 in HPs as an 'early' readout of PLAG function, and in leukemic cells expressing PLAGL2 as a 'leukemic' readout. In this analysis, 23 genes were upregulated over twofold while no repressed genes were found, highlighting the transcription activation role of PLAG proteins. The sustained upregulation of Mpl levels in membrane by PLAGL2 strongly suggests that Mpl is a major player in PLAG-mediated oncogenicity. Consistent with these findings, mutations in the MPL and THPO genes that promote translation and protein stability have been found in the inherited myeloproliferative syndrome familial essential thrombocythemia. 25, 26 In addition, somatic activating mutations in MPL are present in a fraction of patients with myelofibrosis with myeloid metaplasia and essential thrombocythemia. 27, 28 Future studies should evaluate the levels of PLAGL2 and Mpl in myeloproliferative disorders that lack oncogenic mutations in MPL.
Mpl expression is regulated by the ETS, RUNX and GATA factors in megakaryocytes. [29] [30] [31] The Thpo/Mpl pathway is a major regulator of hematopoietic stem cells. [32] [33] [34] However, the mechanism of regulation of Mpl expression in hematopoietic stem cells is not well understood. We identified two PLAG consensus sites within a 180-bp evolutionary conserved region upstream of the Mpl translation initiation site. These sites can be bound by PLAGL2, which upregulates transcription, strongly implicating PlagL2 as regulator of Mpl transcription. Importantly, RUNX-and ETS-binding sites are also located within the Mpl proximal promoter, suggesting that Mpl expression could be regulated by the combinatorial role of multiple transcription factors in megakaryocytes, stem cells and leukemic cells. Future studies should unravel the specific PLAG, RUNX and ETS factors that interact to regulate Mpl expression in different cell types. In addition to the oncogenic role of PLAG1 and PLAGL2, PLAGL1 (the third member of the PLAG family) has been implicated as a tumor suppressor in multiple types of cancer, including breast and ovarian cancer and neck squamous cell carcinomas (reviewed in ref. 35) , and has recently been found repressed in diffuse large B-cell lymphoma. 36 As PLAGL1 binds to the first GC-block, it is also possible that Mpl expression in HPs and leukemia may be affected by PLAGL1-loss of expression. Coexpression analysis of available gene expression data sets of human AML (http://www.oncomine.org) suggest no correlation between PlagL2 and Mpl transcript levels. However, further study of the three PLAG proteins and other factors as modulators of Mpl signaling in human AML is warranted.
The present study demonstrates that PLAGL2 activates expression of Mpl, using two PLAG-consensus-binding sites in its proximal promoter, and activates its downstream signaling in HPs and leukemic cells. This activation is at least one of PLAGL2-induced oncogenic signals that promotes leukemia development in cooperation with CBFb-SMMHC in mice.
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